Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.54 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.54 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | LTA4H | P09960 | 2/20 | 0.52 |
| ▸ | HRH2 | P25021 | 1/20 | 0.52 |
| ▸ | HRH1 | P35367 | 1/20 | 0.52 |
| ▸ | CNR1 | P21554 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | BLM | P54132 | 1/20 | 0.51 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21991489 | 0.92 | CYP1A2 (0.54) | MAPTABCB11LMNAMAPK1CYP1A2 | |
| SCHEMBL19705161 | 0.90 | CYP1A2 (0.52) | MAPTABCB11LMNACYP1A2CYP3A4 | |
| SCHEMBL11566246 | 0.90 | MAPT (0.54) | BRD4CYSLTR2CYSLTR1MAPTABCB11 | |
| SCHEMBL15363151 | 0.89 | PDK2 (0.49) | BRD4CYSLTR2CYSLTR1MAPTABCB11 | |
| Ethane SCHEMBL16527398 | 0.88 | BRD4 (0.48) | BRD4CYSLTR2CYSLTR1MAPTABCB11 | |
| SCHEMBL21991515 | 0.88 | TDP1 (0.50) | MAPTABCB11LMNAMAPK1CYP1A2 | |
| SCHEMBL6937314 | 0.87 | MEN1 (0.62) | BRD4CYSLTR2CYSLTR1MAPTLTA4H | |
| SCHEMBL15363152 | 0.86 | BRD4 (0.46) | BRD4CYSLTR2CYSLTR1MAPTABCB11 | |
| SCHEMBL11566476 | 0.86 | CYP4F2 (0.56) | MAPTABCB11LMNAMAPK1LTA4H | |
| SCHEMBL19692569 | 0.86 | LTA4H (0.70) | LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3704094-B1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES LLC (US) | 2026-03-11 | — | — | EP | disclosed |
| US-20240166652-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ABBVIE INC. | 2024-05-23 | — | — | US | disclosed |
| CN-112657542-B | Method for preparing p-aminophenol from nitrobenzene | 常州大学 | 2023-09-22 | — | — | CN | disclosed |
| US-20230165848-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-06-01 | — | — | US | disclosed |
| US-20230165848-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-06-01 | — | — | US | disclosed |
| US-20230165848-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-06-01 | — | — | US | disclosed |
| US-11547704-B2 | Chemical compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-01-10 | — | — | US | disclosed |
| US-11547704-B2 | Chemical compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-01-10 | — | — | US | disclosed |
| EP-3468960-B1 | CHEMICAL COMPOUNDS AS ATF4 PATHWAY INHIBITORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2022-03-23 | — | — | EP | disclosed |
| CN-109563071-B | Chemical compounds as inhibitors of the ATF4pathway | 葛兰素史密斯克莱知识产权发展有限公司 | 2021-08-03 | — | — | CN | disclosed |
| EP-1877067-A1 | 4-BIARYLYL-1-PHENYLAZETIDIN-2-ONE GLUCURONIDE DERIVATIVES FOR HYPERCHOLESTEROLEMIA | Microbia, Inc. (US) | 2008-01-16 | — | — | EP | disclosed |
| WO-2006124713-A2 | 4-BIARYLYL-1-PHENYLAZETIDIN-2-ONES | MICROBIA, INC. (US) | 2006-11-23 | — | — | WO | disclosed |
| WO-2006122186-A2 | 1,4-DIPHENYL-3-HYDROXYALKYL-2-AZETIDINONE DERIVATIVES FOR TREATING HYPERCHOLESTROLEMIA | MICROBIA, INC. (US) | 2006-11-16 | — | — | WO | disclosed |
| WO-2006121861-A2 | BIPHENYLAZETIDINONE CHOLESTEROL ABSORPTION INHIBITORS | MICROBIA, INC. (US) | 2006-11-16 | — | — | WO | disclosed |
| WO-2006116499-A1 | 4-BIARYLYL-1-PHENYLAZETIDIN-2-ONE GLUCURONIDE DERIVATIVES FOR HYPERCHOLESTEROLEMIA | MICROBIA, INC. (US) | 2006-11-02 | — | — | WO | disclosed |
| US-RE37770-E1 | SUCH AS LINOLEIC ACID, OLEIC ACID, 5,8,11,14-EICOSATETRAYNOIC ACID, 4-CHLORO-6-(2,3-XYLIDINO)-2-PYRIMIDINYL)THIOACETIC ACID, CLOFIBRATE, AND GEMFIBROZIL; USEFUL FOR TREATING DISORDERS OF EPIDERMAL DIFFERENTIATION AND PROLIFERATION. | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2002-06-25 | — | — | US | disclosed |
| US-6187814-B1 | BY TOPICALLY AN FARNESOID X-ACTIVATED RECEPTOR (FXR) ACTIVATOR SELECTED FROM FARNESAL, ALKYL FARNESYL ETHER, ALKYL FARNESOATE, AND 7-METHYL-9-(3,3-DIMETHYLOXIRANYL)-3-METHYL-2,6-NONADIENOIC ACID, ALKYL ESTER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2001-02-13 | — | — | US | disclosed |
| US-6184215-B1 | TOPICALLY APPLYING TO SKIN A HYDROXYCHOLESTEROL TO ACTIVATE LIVER-BASED X-ACTIVATED RECEPTOR ALPHA (LXRA) | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2001-02-06 | — | — | US | disclosed |
| US-6060515-A | TOPICALLY APPLYING TO MAMMALIAN SKIN OR MUCOUS MEMBRANE A BARRIER DEVELOPMENT ENHANCING AMOUNT OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR ALPHA (PPARA) | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2000-05-09 | — | — | US | disclosed |
| CN-1248916-A | Use of FXR, PPAR 'alpha' and LXR 'alpha' activators to restore barrier function, promote epidermal differentiation and inhibit proliferation | UNIV CALIFORNIA (US) | 2000-03-29 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240166652-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ATF4, ATF1, DDIT3 | BRD4 1133/4885CYSLTR2 2729/4885CYSLTR1 2836/4885 |
| US-20230165848-A1 | CHEMICAL COMPOUNDS | ATF4, XBP1, EIF2B5 | BRD4 203/4885CYSLTR2 1557/4885CYSLTR1 1121/4885 |
| US-11547704-B2 | Chemical compounds | ATF4, XBP1, EIF2B5 | BRD4 186/4885CYSLTR2 1602/4885CYSLTR1 1142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.